天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01779 天辰生物-B

未开盘 07-08 16:08:17

95.050

-13.050

-12.07%

最高105.400	最低95.050	成交量10.78万
今开105.100	昨收108.100	日振幅9.57%
总市值72.54亿	流通市值71.34亿	总股本7,632万
成交额1,083万	换手率0.14%	流通股本7,506万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01779","market":"HK","secType":"STK","nameCN":"天辰生物-B","latestPrice":95.05,"timestamp":1783498097741,"preClose":108.1,"halted":0,"volume":107750,"delay":0,"changeRate":-0.12072155411655872,"floatShares":75059200,"shares":76322100,"eps":-2.733,"marketStatus":"未开盘","change":-13.05,"latestTime":"07-08 16:08:17","open":105.1,"high":105.4,"low":95.05,"amount":10828859,"amplitude":0.095745,"askPrice":96.5,"askSize":1500,"bidPrice":95.05,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.547,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783560600000},"marketStatusCode":0,"adr":0,"listingDate":1780588800000,"exchange":"SEHK","adjPreClose":108.1,"openAndCloseTimeList":[[1783474200000,1783483200000],[1783486800000,1783497600000]],"volumeRatio":0.49221141135199564,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01779","defaultTab":"news","newsList":[{"id":"1149362957","title":"天辰生物-B因悉数行使超额配股权配发2,128,950股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1149362957","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149362957?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:24","pubTimestamp":1783337045,"startTime":"0","endTime":"0","summary":"天辰生物-B（01779）于2026年7月6日发布公告，披露公司因悉数行使超额配股权增发H股，涉及的发行及配发股份总数为2,128,950股，变动日期为2026年7月6日。\n根据公告，此次增发的2,128,950股约占本次发行前公司已发行股本的2.92%，每股发行价格为96.06港元。增发完成后，公司已发行股本由72,930,268股增至75,059,218股，库藏股数仍为0股。\n公司于公告中确认已遵守相关上市规则及法律法规。本次披露文件由执行董事谢鸣签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"天辰生物-B因悉数行使超额配股权配发2,128,950股H股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649626332","title":"天辰生物-B(01779)因悉数行使超额配股权而发行212.895万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649626332","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649626332?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:18","pubTimestamp":1783336719,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B(01779)发布公告，于2026年7月6日因悉数行使超额配股权而发行及配发212.895万H股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125387826","title":"天辰生物-B更新2026年6月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125387826","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125387826?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:05","pubTimestamp":1783335959,"startTime":"0","endTime":"0","summary":"天辰生物醫藥(蘇州)股份有限公司于2026年7月6日发布截至2026年6月30日止月份的股份变动月报表。公告显示，公司注册于中华人民共和国，其H股已于2026年6月5日正式在香港联合交易所有限公司主板上市。根据月报表，天辰生物-B于报告期内法定/注册股本总额为人民币74,193,150元，包含72,930,268股H股及1,262,882股未上市股份，均为每股面值人民币1元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648323501","title":"天辰生物-B(01779)：稳定价格行动及稳定价格期结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2648323501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648323501?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:42","pubTimestamp":1782988960,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，本公司宣布，有关全球发售的稳定价格期已于2026年7月2日(星期四)结束。于稳定价格期，稳定价格操作人并无为稳定价格而在市场上购买或出售任何H股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648324573","title":"天辰生物-B创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2648324573","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648324573?lang=zh_cn&edition=full","pubTime":"2026-07-02 09:56","pubTimestamp":1782957411,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02670","02726","BK4585","01511","02672","07630","02696","06675","00068","00340","03310","02272","03625","01236","02553","06656","02335","BK4588","01191","03355","01021","01392","01956","02616","02723","01286","06872","09630","00863","01866","03388","02526","07666","01609","01133","00376","06106","01081","02142","06938","03887","01651","00600","03661","07688","02632","06658","01779","03277","02729","09637","06636","00100","00412","01440","01672","01879"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647755290","title":"天辰生物-B(01779)：超额配股权获悉数行使","url":"https://stock-news.laohu8.com/highlight/detail?id=2647755290","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647755290?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:29","pubTimestamp":1782829773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B(01779)公布，独家保荐人兼整体协调人(为其本身及代表国际包销商)已于2026年 6月30日(星期二)悉数行使招股章程所述的超额配股权，涉及合共212.895万股H 股，占于任何超额配股权获行使前全球发售项下初步可供认购发售股份总数的约 15%。因超额配股权获行使而将予发行的H股将由公司按每股H股 96.06港元配发及发行。超额配发股份将用于促成将部分H股交付予已同意延迟交付其根据全球发售认购的相关H股的承配人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647958949","title":"港股异动 | 天辰生物-B(01779.HK)涨超6% LP-003针对季节性过敏性鼻炎适应症III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2647958949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647958949?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:02","pubTimestamp":1782788555,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647589491","title":"港股异动 | 天辰生物-B(01779)涨超6% LP-003针对季节性过敏性鼻炎适应症III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2647589491","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647589491?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:02","pubTimestamp":1782788555,"startTime":"0","endTime":"0","summary":"消息面上，近日，天辰生物-B发布公告，LP-003针对季节性过敏性鼻炎的III期临床试验已达到预先设定的主要终点，且该等结果在统计学及临床方面均具有高度重要性。LP-003针对季节性过敏性鼻炎适应症的III期临床试验是一项在中国开展的多中心、随机、双盲、安慰剂对照的III期临床研究，旨在比较LP-003与安慰剂治疗经标准治疗控制不佳的中重度季节性过敏性鼻炎的效果。此外，LP-003 II期临床数据初步展现出超越奥马珠单抗的潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","BK1161","01779","VXUS","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237531","title":"天辰生物-B(01779)：LP-003针对季节性过敏性鼻炎适应症的III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237531","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642237531?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:16","pubTimestamp":1781216203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，LP-003针对季节性过敏性鼻炎的III期临床试验已达到预先设定的主要终点，且该等结果在统计学及临床方面均具有高度重要性。LP-003针对季节性过敏性鼻炎适应症的III期临床试验是一项在中国开展的多中心、随机、双盲、安慰剂对照的III期临床研究，旨在比较LP-003与安慰剂治疗经标准治疗控制不佳的中重度季节性过敏性鼻炎的效果。主要排除标准为患有季节性过敏性鼻炎以外的合并症的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1123467918","title":"天辰生物-B：LP-3治疗季节性过敏性鼻炎III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123467918","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123467918?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:13","pubTimestamp":1781215995,"startTime":"0","endTime":"0","summary":"天辰生物-B宣布，其用于治疗季节性过敏性鼻炎的候选药物LP-3，在关键的III期临床试验中成功达到了预设的主要疗效终点。这一积极结果标志着该药物在临床开发道路上取得了重大进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462623","title":"进入最后一个月倒计时，天辰生物-B(01779)能否在入通前撑起高位估值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462623","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642462623?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:26","pubTimestamp":1781004367,"startTime":"0","endTime":"0","summary":"上市次日，天辰生物场内表现较为低迷，股价全天在水下波动，最终收跌6.83%。此次天辰生物的发行比例是19.13%，基石锁定49.96%，流通盘约为6.82亿港元，其释出的公开发售数量为28387手，并且入场费达到4851.44港元。目前天辰生物检讨周期内日平均市值为90.77亿港元，市值覆盖率为94.61%，而截至6月8日公司收盘价为124港元。但就在这种情况下，天辰生物的此次IPO发行市值却达到了71.27亿港元，较C轮估值大涨226.57%，而这在短期内或透支了公司估值成长预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118653094","title":"异动解读｜天辰生物-B盘中上涨6.37%，上市次日延续IPO超购热度","url":"https://stock-news.laohu8.com/highlight/detail?id=1118653094","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118653094?lang=zh_cn&edition=full","pubTime":"2026-06-09 09:33","pubTimestamp":1780968791,"startTime":"0","endTime":"0","summary":"6月9日，天辰生物-B盘中上涨6.37%，报139.3港元，成交额775.71万港元，较招股价96.06港元累计溢价约45%。消息面上，天辰生物-B于6月5日正式登陆港交所，其香港公开发售部分获得高达4762.58倍超额认购，一手中签率仅约2%，市场认购热情极高。天辰生物是一家临床阶段生物制药公司，专注于过敏性及自身免疫性疾病生物药物的自主发现与开发，核心产品LP-003为抗IgE抗体，已在中国启动八项临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641168031","title":"港股收盘(06.05) | 恒指收跌1.15%失守两万五 半导体股显著回调 三新股首日表现分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2641168031","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641168031?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:32","pubTimestamp":1780648331,"startTime":"0","endTime":"0","summary":"截至收盘，恒生指数跌1.15%或291.45点，报24961.95点，全日成交额3428.05亿港元；恒生国企指数跌0.77%，报8436.63点；恒生科技指数跌1.75%，报4888.39点。截至收盘，涨6%，报143.2港元，成交额3亿港元，贡献恒指1.67点。截至收盘，澜起科技跌9.21%，报368.8港元；兆易创新跌8.02%，报723.0港元；中芯国际跌7.18%，报75.65港元；华虹半导体跌7.16%，报145.3港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00981","SSG","03143","LU1152091754.HKD","PSI","513600","LU0067412154.USD","00316","XSD","LU0149534421.HKD","SOXS","SOXY","07300","BK1163","02800","07200","82800","SG9999000327.SGD","SOXX","VGT","03115","SMHX","USD","MHImain","159582","LU0211977185.USD","HHImain","STAN.UK","VXUS","06809","MCHmain","SMH","09115","02833","TEKX","07500","01779","83115","02888","02290","BK1526","SOXQ","CHPS","FTXL","SOXL","03419","HSImain","03037","HSI","CHPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193234584","title":"异动解读 | 天辰生物-B首日挂牌盘中大涨54.80%，获超4700倍超额认购引爆市场热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1193234584","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193234584?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:35","pubTimestamp":1780623326,"startTime":"0","endTime":"0","summary":"天辰生物-B今日盘中大幅上涨54.80%，成为市场关注的焦点。消息面上，天辰生物-B今日正式在港交所主板挂牌上市，作为首日挂牌的新股，其香港公开发售部分获得了高达4762.58倍的超额认购，显示出市场极高的认购热情和资金追捧。此前暗盘交易该股已录得显著涨幅，为上市首日的强势表现奠定了基调。天辰生物-B是一家临床阶段的生物制药公司，专注于针对过敏性及自身免疫性疾病的生物药物研发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188921822","title":"异动解读｜天辰生物-B盘中上涨51.05%，首挂上市获超4762倍超额认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1188921822","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188921822?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:30","pubTimestamp":1780623042,"startTime":"0","endTime":"0","summary":"6月5日，天辰生物-B首日挂牌上市，盘中上涨51.05%，报145.0港元，成交额3.02亿港元，较招股价96.06港元大幅溢价。消息面上，天辰生物-B本次IPO公开发售部分获4762.58倍超额认购，共接获约26.64万份有效申请，一手中签率仅约2%。此前暗盘交易报225.8港元，较招股价上涨逾135%，市场认购热情极高。天辰生物是一家临床阶段生物制药公司，专注于过敏性及自身免疫性疾病的生物药物自主发现与开发，核心产品LP-003为抗IgE抗体，已在中国启动八项临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641964196","title":"新股首日 | 天辰生物-B(01779)首挂上市 早盘高开50.22% 核心产品LP-003已在中国启动八项临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2641964196","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641964196?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:21","pubTimestamp":1780622509,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天辰生物-B首挂上市，公告显示，每股定价96.06港元，共发行1419.32万股股份，每手50股，所得款项净额约12.55亿港元。截至发稿，涨50.22%，报144.3港元，成交额2.99亿港元。公开资料显示，天辰生物是一家临床阶段生物制药公司，主要专注于针对过敏性及自身免疫性疾病的生物药物的自主发现与开发。公司的核心产品LP-003是一种抗IgE抗体，已在中国启动八项临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107086499","title":"港股开盘 | 恒指低开0.27%，科指低开0.31%！天辰生物-B首挂涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107086499","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107086499?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:20","pubTimestamp":1780622430,"startTime":"0","endTime":"0","summary":"6月5日，恒生指数开盘下跌67.28点，跌幅0.27%，报25186.12点；恒生科技指数开盘下跌15.43点，跌幅0.31%，报4959.93点；国企指数开盘下跌8.36点，跌幅0.1%，报8493.55点；红筹指数开盘下跌25.99点，跌幅0.59%，报4394.52点。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["82800","07500","09115","09088","BK4585","HSI","03037","513600","03033","07226","83115","03419","HSTECH","VXUS","09067","03067","02833","07552","03088","03423","07300","03032","01779","03115","02837","07200","02800","03417","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127260818","title":"新股定价 | 天辰生物-B每股定价96.06港元，公开发售超购4762.58倍，一手中签率2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127260818","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127260818?lang=zh_cn&edition=full","pubTime":"2026-06-05 07:57","pubTimestamp":1780617420,"startTime":"0","endTime":"0","summary":"天辰生物-B（01779）公布配发结果。公司全球发售股份共计1419.315万股，最终发售价为每股96.06港元，募资净额约12.55亿港元，每手买卖单位为50股。H股预计于2026年6月5日（星期五）上午九时正起在联交所开始买卖。其中，香港公开发售部分获得4762.58倍超额认购，最终发售股份数目为141.94万股，占发售股份总数的10%。该部分共接获约26.64万份有效申请，受理申请数目约28057份，申购一手股份的获配发比例约为所申请股份总数的2%。国际配售部分获得10.94倍超额认购，最终发售股份数目为1277.38万股，占发售股份总数的90%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/dd692af5834cccf0a1114930c5817827","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/dd692af5834cccf0a1114930c5817827"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640082163","title":"天辰生物-B(01779)：香港公开发售获4762.58倍认购 全球发售净筹约12.55亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640082163","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640082163?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:29","pubTimestamp":1780583353,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B(01779)公布配发结果，公司全球发售1419.315万股股份，香港公开发售占10%，国际发售占90%。最终发售价为每股96.06港元，全球发售净筹约12.55亿港元。每手50股，预期H股将于2026年6月5日(星期五)上午九时正(香港时间)开始在联交所买卖。其中，香港公开发售获4,762.58倍认购，国际发售获10.94倍认购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longbio.com","stockEarnings":[{"period":"1week","weight":-0.3701},{"period":"1month","weight":-0.2335},{"period":"3month","weight":-0.0105},{"period":"ytd","weight":-0.0105}],"compareEarnings":[{"period":"1week","weight":0.0576},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0603},{"period":"6month","weight":-0.0775},{"period":"1year","weight":0.0021},{"period":"ytd","weight":-0.0558}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"天辰生物医药（苏州）股份有限公司是一家主要从事过敏性及自身免疫性疾病的生物药物自主发现与开发的中国公司。该公司的研发平台主要包括高亲和力抗体发现平台和双功能抗体开发平台。该公司的药物治疗方向主要包括季节性过敏性鼻炎（AR）、慢性自发性荨麻疹（CSU）、过敏性哮喘、食物过敏以及其他过敏性疾病、阵发性睡眠性血红蛋白尿症（PNH）、补体介导肾脏疾病、C3肾小球病（C3G）和狼疮性肾炎（LN）及其他补体相关适应症。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"天辰生物-B","nameEN":"LONGBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天辰生物-B(01779)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天辰生物-B,01779,天辰生物-B股票,天辰生物-B股票老虎,天辰生物-B股票老虎国际,天辰生物-B行情,天辰生物-B股票行情,天辰生物-B股价,天辰生物-B股市,天辰生物-B股票价格,天辰生物-B股票交易,天辰生物-B股票购买,天辰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天辰生物-B(01779)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}